Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New Study Alert: CAR-T Prep Reimagined! Can bendamustine replace Flu/Cy as lymphodepleting chemotherapy before CAR-T in relapsed/refractory NHL?
In a large real-world study (n=265), bendamustine showed:
Comparable OS and PFS
Less severe neutropenia (71% vs. 17%)
Greater feasibility in outpatient settings
A promising alternative amidst global fludarabine shortages. Time to rethink how we prep for CART therapy? Kaplan-Meier and Cox models adjusted for CAR-T product, year, subtype, and steroid use.”
Title: Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Authors: Uttam K. Rao, Navneet S. Majhail, Betsy Blunk, Karin Abernathy, Carlos Bachier, Vikas Bhushan, Jose Carlos Cruz, Mohammed Elayan, Tara Gregory, Charles F. LeMaistre, Shahbaz A. Malik, Casey Martin, Meredith Mattlin, Gabrielle Blade, Michael B. Maris, John Mathews, Luke Mountjoy, Jeremy M. Pantin, Aravind Ramakrishnan, Paul Shaughnessy, Minoo Battiwalla
Read the Full Article.
More posts featuring Yan Leyfman.